The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease

NCT06167681 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease

Interventions

BIOLOGICAL: Human Dopaminergic Progenitor Cells

Sponsor

iRegene Therapeutics Co., Ltd.